L01XA03 - Oxaliplatin |
Propably not porphyrinogenic |
PNP |
Rationale
Non-CYP metabolism. However, side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Chemical description
Oxaliplatin is an organoplatinum complex, consisting of a platinum atom complexed with 1,2-diaminocyclohexane (DACH) and a labile oxalate ligand.
Therapeutic characteristics
Oxaliplatin is a platinum-containing antineoplastic agent used as adjuvant treatment in advanced colon cancer and as part of combination therapy in the treatment of advanced cancer of the colon and rectum. It is administered as an intravenous infusion. Common adverse reactions of oxaliplatin that can be confused with an acute porphyric attack are vomiting, nausea, obstipation, abdominal pain, back pain, peripheral sensoric neuropathy, depression and insomnia. Side effects such as nausea, anorexia and vomiting may be potentially porphyrinogenic through reduction in caloric intake.
Metabolism and pharmakokinetics
Oxaliplatin undergoes rapid and extensive nonenzymatic biotransformation; no evidence of CYP-mediated metabolism in vitro. Eliminated principally by renal excretion. Interactions with CYP metabolism of other drugs not observed. Not listed as CYP-inducer or inhibitor (Rendic, 2002).
IPNet drug reports
Uneventful use reported in 1 patient with acute porphyria.
References
- Scientific articles
- Rendic, S. Summery of information on human CYP enzymes: human P450 metabolism. Drug metabolism reviews 2002; 34(1&2), 83-448. #1025
- Drug reference publications
- McEvoy GK, editor. Oxaliplatin. The AHFS Drug Information 2008. Bethesda, MD: American Society of Health-System Pharmacists; 2009. Electronic version (10.05.10). #2030
- Sweetman SC, editor. Martindale: The complete drug reference. Oxaliplatin. Pharmaceutical Press 2009. #2032
- Summary of Product Characteristics
- Norwegian medicines agency. Summary of Product Characteristics (SPC). Eloxatin. #2031
Similar drugs
© NAPOS 2024